Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Insight - Stem cells: the unsteady rise of the East?

This article was originally published in Scrip

Executive Summary

South Korea has had an unsteady early relationship with stem cell research and the country has yet to recover fully from the high-profile Hwang Woo-Suk cloning scandal of 2006. This South Korean scientist famously and fraudulently reported to have succeeded in creating human embryonic stem (hES) cells by nuclear transfer. The scandal received widespread coverage in the media and dealt a terrible blow to the country on the embryonic stem cell research stage. Yet, the hero status bestowed on Dr Hwang before his downfall indicated that Asian governments supported, and that their communities were ready for, stem cell therapies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC030838

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel